54-12-6Relevant academic research and scientific papers
Dynamic Kinetic Resolution for Asymmetric Synthesis of L-Noncanonical Amino Acids from D-Ser Using Tryptophan Synthase and Alanine Racemase
Yu, Jinhai,Li, Jing,Gao, Xia,Zeng, Shuiyun,Zhang, Hongjuan,Liu, Junzhong,Jiao, Qingcai
, p. 6618 - 6625 (2019/11/03)
L-Ser is often used to synthesize some significant l-noncanonical α-amino acids(l-ncAAs), which are the prevalent intermediates and precursors for functional synthetic compounds. In this study, threonine aldolase from Escherichia coli k-12 MG1655 has been used to synthesize l-Ser. In contrast to the maximum catalytic capacity (20 g/L) for l-threonine aldolase(LTA), d-Ser was synthesized with high yield (240 g/L) from cheap Gly and paraformaldehyde using d-threonine aldolase (DTA) from Arthrobacter sp ATCC. In order to fully utilize d-Ser and expand the resource of l-Ser, a dynamic kinetic resolution system was constructed to convert d/dl-Ser to l-Ser through combining alanine racemase (Alr) from Bacillus subtilis with l-tryptophan synthase (TrpS) from Escherichia coli k-12 MG1655, and l-ncAAs including l-Trp and l-Cys derivatives were synthesized with excellent enantioselectivity and in high yields. The results indicated l-ncAAs could be efficiently synthesized from d-Ser using this original and green dynamic kinetic resolution system, and the reliable l-Ser resource has been established from simple and achiral substrates.
Organocatalytic Enantioselective Addition of α-Aminoalkyl Radicals to Isoquinolines
Liu, Xiangyuan,Liu, Yang,Chai, Guobi,Qiao, Baokun,Zhao, Xiaowei,Jiang, Zhiyong
supporting information, p. 6298 - 6301 (2018/10/09)
With a dual organocatalytic system involving a chiral phosphoric acid and a dicyanopyrazine-derived chromophore (DPZ) photosensitizer and under the irradiation with visible light, an enantioselective Minisci-type addition of α-amino acid-derived redox-active esters (RAEs) to isoquinolines has been developed. A variety of prochiral α-aminoalkyl radicals generated from RAEs were successfully introduced on isoquinolines, providing a range of valuable α-isoquinoline-substituted chiral secondary amines in high yields with good to excellent enantioselectivities.
Feed additive method for preparing DL-tryptophan
-
Paragraph 0027; 0037; 0038, (2016/10/07)
The invention provides a method for preparing a feed additive DL-tryptophan. The method comprises the following steps of: 1) preparing indole-3-formaldehyde; 2) preparing aceturic acid; 3) preparing 3-indolyl-2-acetamino acrylic acid; 4) preparing N-acetyltryptophan; 5) preparing the DL-tryptophan. The method for preparing the feed additive DL-tryptophan is easy in acquisition of raw materials, low in raw material cost, high in reaction efficiency, and simple in process; the method can be carried out at the normal temperature and under the normal pressure without environmental pollution.
Two-photon sensitive protecting groups operating via intramolecular electron transfer: Uncaging of GABA and tryptophan
Korzycka, Karolina A.,Bennett, Philip M.,Cueto-Diaz, Eduardo Jose,Wicks, Geoffrey,Drobizhev, Mikhail,Blanchard-Desce, Mireille,Rebane, Aleksander,Anderson, Harry L.
, p. 2419 - 2426 (2015/03/30)
Improved photo-labile protecting groups, with high sensitivity to two-photon excitation, are needed for the controlled release of drugs, as tools in neuroscience and physiology. Here we present a new modular approach to the design of caging groups based on photoinduced electron transfer from an electron-rich two-photon dye to an electron acceptor, followed by scission of an ester to release a carboxylic acid. Three different electron acceptors were tested: nitrobenzyl, phenacyl and pyridinium. The nitrobenzyl system was ineffective, giving only photochemical decomposition and no release of the carboxylic acid. The phenacyl system also performed poorly, liberating the carboxylic acid in 20% chemical yield and 0.2% photochemical yield. The pyridinium system was most successful, and was tested for the release of two carboxylic acids: γ-amino butyric acid (GABA) and tryptophan. The caged GABA undergoes photochemical cleavage with a chemical yield of >95% and a photochemical yield of 1%; it exhibits a two-photon absorption cross section of 1100 GM at 700 nm, corresponding to a two-photon uncaging cross section of 10 ± 3 GM. This journal is
Peptidomimetics comprising N-amino cyclic urea residues and uses thereof
-
Page/Page column, (2015/04/15)
Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed. Use of such peptidomimetics for modulating the activity of CD36 or IL-1 receptor in a cell, and for treating CD36- or IL-1-related disease, disorder or condition is also described.
PEPTIDOMIMETICS COMPRISING N-AMINO CYCLIC UREA RESIDUES AND USES THEREOF
-
Page/Page column, (2014/02/16)
Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed. Use of such peptidomimetics for modulating the activity of CD36 or IL-1 receptor in a cell, and for treating CD36- or IL-1-related disease, disorder or condition is also described
PEPTIDES CONTAINING TRYPTOPHAN
-
, (2011/04/25)
The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45.
MIXTURE OF PEPTIDE-BOUND TRYPTOPHAN AND POLYPEPTIDE-BOUND TRYPTOPHAN
-
, (2011/05/16)
The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.
Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
-
, (2010/02/16)
The present invention provides a novel family of polypeptides which are ligand-gated channel receptor accessory molecules or ligands, denoted Lynx. This invention provides an isolated polypeptide comprising an amino acid sequence of a Lynx polypeptide in which the amino acid sequence is set forth in SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:15, including fragments, mutants, variants, analogs, homologs, or derivatives, thereof. This invention further provides an isolated immunogenic polypeptide comprising an amino acid sequence of a Lynx polypeptide and relates to antibodies of Lynx polypeptides and the use of such antibodies. The invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a Lynx polypeptide. This invention provides pharmaceutical compositions and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids of the present invention. Assays for compounds which mimic, alter or inactivate the polypeptides of the present invention for use in therapy are also provided. The present invention further relates to methods of isolating Lynx polypeptides and the nucleic acids encoding such polypeptides.
AGENT FOR PREVENTING/TREATING CANCER
-
, (2010/02/17)
A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on.
